Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Executive Summary

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.


Related Content

When It Comes To FTC M&A Review, The Times May Be A Changin'
Eisai Joins PROTAC Club Through New Oncology Collab
Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug
As China Dives Into RWE, J&J Teams Up To Tackle Depression
AbbVie-Allergan in India – Brimming With Opportunities?
Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio
Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development
Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal
Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach
Will Radiopharmaceutical Company AAA Be M&A Fodder For Novartis?


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts